Ilkka Kantola

An expert consensus on the recommendations for the use of biomarkers in Fabry disease (2023)

Molecular Genetics and Metabolism

Burlina Alessandro, Brand Eva, Hughes Derralynn, Kantola Ilkka, Krӓmer Johannes, Nowak Albina, Tøndel Camilla, Wanner Christoph, Spada Marco

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study (2023)

American Journal of Medical Genetics Part A

Pietilä-Effati Päivi, Saarinen Jukka T, Löyttyniemi Eliisa, Saarenhovi Maria, Autio Reijo, Kantola Ilkka

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study (2023)

Journal of Medical Genetics

Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V, Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF) (2023)

Primary Care Diabetes

Metsärinne Kaj, Pietilä Mikko, Kantola Ilkka, K Stenman Lotta, Vesikansa Aino, Ruokolainen Lasse, Niskanen Leo; STONE HF (STages Of NEphropathy in type 2 diabetes and Heart Failure) study investigators

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation (2023)

Open Heart

Valtola Kati, Hedman Marja, Kantola Ilkka, Walls Susanne, Helisalmi Seppo, Maria Maleeha, Raivo Joose, Auray-Blais Christiane, Kuusisto Johanna

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Fabryn tauti (2023)

Kantola Ilkka

(Artikkeli ammatillisessa kokoomateoksessa (D2))

Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry (2023)

Molecular Genetics and Metabolism

Hopkin Robert J, Cabrera Gustavo H, Jefferies John L, Yang Meng, Ponce Elvira, Brand Eva, Feldt-Rasmussen Ulla, Germain Dominique P, Guffon Nathalie, Jovanovic Ana, Kantola Ilkka, Karaa Amel, Martins Ana M, Tøndel Camilla, Wilcox William R, Yoo Han-Wook, Burlina Alessandro P, Mauer Michael

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring (2023)

iScience

Panula Tuukka, Sirkiä Jukka-Pekka, Koivisto Tero, Pänkäälä Mikko, Niiranen Teemu, Kantola Ilkka, Kaisti Matti

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

THE CHANGE IN QUALITY OF LIFE IN DRUG TREATED HYPERTENSIVE PATIENTS AFTER 10 YEARS OF ANTIHYPERTENSIVE TREATMENT (2022)

Journal of Hypertension

Kantola Ilkka M., Kantola Taru

(Muu (O2))

Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation (2022)

Molecular Genetics and Genomic Medicine

Pietilä-Effati Päivi, Söderström Johan, Saarinen Jukka T, Löyttyniemi Eliisa, Kantola Ilkka

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

An expert consensus on the recommendations for the use of biomarkers in Fabry disease (2023)

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study (2023)

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study (2023)

Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF) (2023)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation (2023)

Fabryn tauti (2023)

Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry (2023)

Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring (2023)

THE CHANGE IN QUALITY OF LIFE IN DRUG TREATED HYPERTENSIVE PATIENTS AFTER 10 YEARS OF ANTIHYPERTENSIVE TREATMENT (2022)

Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation (2022)